0002001011-24-000027.txt : 20240229 0002001011-24-000027.hdr.sgml : 20240229 20240229184956 ACCESSION NUMBER: 0002001011-24-000027 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240227 FILED AS OF DATE: 20240229 DATE AS OF CHANGE: 20240229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davis Todd C CENTRAL INDEX KEY: 0001392029 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 24706120 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0508 4 2024-02-27 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001392029 Davis Todd C 3911 SORRENTO VALLEY, SUITE 110 SAN DIEGO CA 92121 1 1 0 0 CHIEF EXECUTIVE OFFICER 0 Common Stock 2024-02-27 4 A 0 32436 0.0 A 104145 D Employee Stock Option (right to buy) 89.2 2024-02-27 4 A 0 131723 0.0 A 2034-02-27 Common Stock 131723 131723 D Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis 2024-02-29